Skip to main content

Table 1 Progression-free survival by subgroup

From: Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Patients (n, XVd vs Vd) Median PFS, months (95% CI) HR (95% CI) P value
XVd Vd
1 prior line (99 vs 99) 16.62 (13.24, NR) 10.68 (7.26, 16.39) 0.6295 (0.4133, 0.9586) 0.0148
2–3 prior lines (96 vs 108) 11.76 (7.39, NR) 9.43 (6.83, 9.69) 0.6949 (0.4760, 1.0147) 0.0295
Lenalidomide naïve (118 vs 130) 16.62 (12.98, NR) 10.61 (8.44, 15.41) 0.6619 (0.4548, 0.9634) 0.0150
Lenalidomide treated (77 vs 77) 9.59 (6.70, NR) 7.23 (4.93, 9.69) 0.6348 (0.4148, 0.9714) 0.0177
PI naïve (47 vs 48) NR (NR, NR) 9.69 (8.44, NR) 0.2585 (0.1116, 0.5988) 0.0003
PI treated (148 vs 159) 11.73 (7.95, 15.21) 9.43 (7.06, 10.71) 0.7839 (0.5791, 1.0612) 0.0576
IMiD refractory (74 vs 86) 13.93 (6.70, NR) 8.44 (5.78, 9.56) 0.5752 (0.3753, 0.8816) 0.0051
Prior bortezomib only as induction for ASCT (37 vs 30) 13.14 (11.73, NR) 9.43 (5.75, NR) 0.5807 (0.2860, 1.1791) 0.0639
ASCT (76 vs 63) 16.56 (9.59, NR) 9.43 (5.91, 10.87) 0.5527 (0.3411, 0.8955) 0.0074
No ASCT (119 vs 144) 13.24 (10.18, NR) 9.56 (8.11, 13.60) 0.7239 (0.5111, 1.0252) 0.0341
  1. ASCT autologous stem cell transplant, CI confidence interval, IMiD immunomodulatory drug, NR not reached, ORR overall response rate, PFS progression-free survival, PI proteasome inhibitor